Skip to content

AvePoint, Inc. AVPT Company Earnout Shares Issuance

Company Earnout Shares Issuance at other companies

NewAmsterdam Pharma Company logo
NewAmsterdam Pharma CompanyNAMS
$40.81M
DJT
Trump Media & Technology GroupDJT
$0
PRD
Perdoceo EducationPRDO
$1.76M
Arthur J. Gallagher logo
Arthur J. GallagherAJG
$115M+945%
Blue Owl Capital logo
Blue Owl CapitalOWL
$147.6M-51.8%
Sterling Infrastructure, Inc. logo
Sterling Infrastructure, Inc.STRL
$2.49M+85.3%

Other financials

Income statement

See full
Revenue$117.2M+26.0%
Gross profit$85.4M+23.4%
Operating income$12.7M+287%
Net income$15.3M+343%
EPS (diluted)$0.07+250%

Balance sheet

See full
Cash & equivalents$444.1M+26.4%
Total debt$22.0M+22.2%
Total equity$200.1M-14.0%
Total assets$734.2M+22.6%

Cash flow

See full
Operating cash flow$24.3M+4,801%
CapEx$1.3M-15.7%
Free cash flow$23.0M+2,355%

Valuation

See full
Market cap$2.2B-29.9%

Profitability

See full
Gross margin73.7%-1.7pp
Operating margin9.6%+5.7pp
Net margin10.5%+7.6pp
FCF margin23.8%+1.6pp

Returns & leverage

See full
Return on equity-17.9%+3.5pp
Debt / equity0.0×
Current ratio2.2×0.0×

Where this comes from

Reported directly by AvePoint, Inc. in its filing.

Tagged under the XBRL concept avpt:CompanyEarnoutSharesIssuance.

The official record: AvePoint, Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about AvePoint, Inc.'s company earnout shares issuance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AvePoint, Inc.'s company earnout shares issuance?
AvePoint, Inc. (AVPT) reported company earnout shares issuance of $0 in Q4 2025.
How has AvePoint, Inc.'s company earnout shares issuance changed year-over-year?
AvePoint, Inc.'s company earnout shares issuance decreased by 100.0% year-over-year, from $13.47M to $0.
What does company earnout shares issuance mean?
This metric represents the issuance of equity instruments to former owners of an acquired business contingent upon the achievement of specific performance milestones post-acquisition. It serves as a mechanism to align the interests of the acquired entity's management with the long-term growth objectives of the parent company. Investors monitor this to assess potential future dilution and the total effective purchase price of inorganic growth initiatives.